Abstract 447P
Background
The addition of chemotherapy to Gefitinib improved outcomes in non-small cell lung cancer (NSCLC) with sensitizing EGFR mutations in this trial, these results have already been published. Here we analysed the quality of life (QoL) data of patients in this study to determine the impact of the addition of chemotherapy to Gefitinib on QoL.
Methods
This was a phase III randomized trial in treatment-naive patients with advanced NSCLC with an EGFR-sensitizing mutation and ECOG PS of 0 -2 receiving first-line palliative therapy. Patients were randomized 1:1 to receive either gefitinib 250 mg PO once a day (Gef) or gefitinib 250 mg PO once a day with Pemetrexed (500 mg/m2) + Carboplatin (AUC5) IV every 3 weeks for 4 cycles, followed by maintenance pemetrexed (gefitinib plus chemotherapy [Gef+C]). The primary endpoint was PFS; QoL was a key secondary endpoint. QoL was assessed using the EORTC QLQ C-30 and LC 13 questionnaires and their validated translations. QoL was collected at 2 monthly intervals [60 (+/-15) days]. The mean QoL scores for both arms were plotted and compared between the two arms at each time point using the Mann-Whitney Test. Sensitivity analysis was performed. The mixed linear model analysis is used to study the impact of treatment arms and time on QoL scores while considering participant variability.
Results
In the linear mixed model analysis (LMA), there was no significant impact on the global health status (QL) scores between the 2 arms (p= 0.5007). However, there was a significant change in the global health status scores in both arms over time (p= 0.0420). In the LMA there were no significant differences in the other function scales between the 2 arms. The scores for the symptoms scale had significantly improved for pain (p = 0.0351), dyspnoea (p = 0.0483), diarrhea (p = 0.0243), sore mouth (p = 0.0283), pain in the arm or shoulder (p = 0.0315), pain in other parts (p = 0.0273) improved over time in the Gef+C arm as compared Gef arm.
Conclusions
The addition of chemotherapy to Gefitinib improved survival outcomes (PFS an dOS) without a significant adverse impact on quality of life.
Clinical trial identification
CTRI/2016/08/007149.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Tata Memorial Center Research Administration Council and unrestricted educational grants from Dr. Reddy’s Laboratories, Fresenius Kabi India, Alkem Laboratories, Natco Pharma, BDR Pharmaceuticals, and Lung Cancer Consortium India.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
623P - Advances in methylation analysis of liquid biopsy in early cancer detection of colorectal and lung cancer
Presenter: Sam Martin
Session: Poster Display
Resources:
Abstract
624P - Pan-cancer single-cell isoform atlas: Unraveling isoform dynamics in cancer immunotherapy
Presenter: Lu Pan
Session: Poster Display
Resources:
Abstract
625P - The association of tumor marker concentration and air pollution in cancer survivors and the general population
Presenter: Kyae Hyung Kim
Session: Poster Display
Resources:
Abstract
626P - Percentage of cancer patients undergoing adjusted targeted therapy after ctDNA testing: Insights from a tertiary hospital experience
Presenter: Jisook Yim
Session: Poster Display
Resources:
Abstract
627P - Racial disparities in synchronous and metachronous colorectal and prostate cancer: SEER based study 2000-2020
Presenter: Taha Nagib
Session: Poster Display
Resources:
Abstract